Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
Study sponsor: Vanda Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-10-14Actual
Enrollment · participants87Actual
Source updated2024-05-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.